These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36752338)

  • 61. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
    Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
    Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Deep Learning and Structure-Based Virtual Screening for Drug Discovery against NEK7: A Novel Target for the Treatment of Cancer.
    Aziz M; Ejaz SA; Zargar S; Akhtar N; Aborode AT; A Wani T; Batiha GE; Siddique F; Alqarni M; Akintola AA
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807344
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
    Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
    Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A combination strategy of structure-based virtual screening, MM-GBSA, cross docking, molecular dynamics and metadynamics simulations used to investigate natural compounds as potent and specific inhibitors of tumor linked human carbonic anhydrase IX.
    Chahal V; Kakkar R
    J Biomol Struct Dyn; 2023; 41(12):5465-5480. PubMed ID: 35735269
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting p53-MDM2 interactions to identify small molecule inhibitors for cancer therapy: beyond "Failure to rescue".
    Chukwuemeka PO; Umar HI; Iwaloye O; Oretade OM; Olowosoke CB; Elabiyi MO; Igbe FO; Oretade OJ; Eigbe JO; Adeojo FJ
    J Biomol Struct Dyn; 2022; 40(19):9158-9176. PubMed ID: 33988074
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Estrogen receptor potentially stable conformations from molecular dynamics as a structure-based pharmacophore model for mapping, screening, and identifying ligands-a new paradigm shift in pharmacophore screening.
    Shanmugarajan D; David C
    J Biomol Struct Dyn; 2023 Jul; 41(11):4939-4948. PubMed ID: 35543232
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Deciphering the Interactions of Bioactive Compounds in Selected Traditional Medicinal Plants against Alzheimer's Diseases via Pharmacophore Modeling, Auto-QSAR, and Molecular Docking Approaches.
    Ojo OA; Ojo AB; Okolie C; Nwakama MC; Iyobhebhe M; Evbuomwan IO; Nwonuma CO; Maimako RF; Adegboyega AE; Taiwo OA; Alsharif KF; Batiha GE
    Molecules; 2021 Apr; 26(7):. PubMed ID: 33915968
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
    Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A combination of pharmacophore modeling, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on PDE4 enzyme inhibitors.
    Tripuraneni NS; Azam MA
    J Biomol Struct Dyn; 2016 Nov; 34(11):2481-92. PubMed ID: 26587754
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors.
    Shah BM; Modi P; Trivedi P
    J Biomol Struct Dyn; 2021 Apr; 39(6):2021-2043. PubMed ID: 32242496
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    Shirvani P; Fassihi A
    J Biomol Struct Dyn; 2022 Aug; 40(13):5965-5982. PubMed ID: 33475043
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
    Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
    J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.
    Razzaghi-Asl N; Ebadi A; Shahabipour S; Gholamin D
    J Biomol Struct Dyn; 2021 Oct; 39(17):6633-6648. PubMed ID: 32705953
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery of novel HDAC8 inhibitors from natural compounds by in silico high throughput screening.
    Esther Rubavathy SM; Palanisamy K; Priyankha S; Thilagavathi R; Prakash M; Selvam C
    J Biomol Struct Dyn; 2023 Nov; 41(19):9492-9502. PubMed ID: 36369945
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach.
    Fadaka AO; Aruleba RT; Sibuyi NRS; Klein A; Madiehe AM; Meyer M
    J Biomol Struct Dyn; 2022 May; 40(8):3416-3427. PubMed ID: 33200673
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
    Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    Sheoran S; Arora S; Basu T; Negi S; Subbarao N; Kumar A; Singh H; Prabhu D; Upadhyay AK; Kumar N; Vuree S
    J Biomol Struct Dyn; 2024 Oct; 42(17):9105-9117. PubMed ID: 37615411
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In-silico and in-vitro anti-cancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione.
    Sufi SA; Adigopula LN; Syed SB; Mukherjee V; Coumar MS; Rao HS; Rajagopalan R
    Biomed Pharmacother; 2017 Jan; 85():389-398. PubMed ID: 27889234
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Discovery of Novel Human Epidermal Growth Factor Receptor-2 Inhibitors by Structure-based Virtual Screening.
    Shi Z; Yu T; Sun R; Wang S; Chen XQ; Cheng LJ; Liu R
    Pharmacogn Mag; 2016; 12(46):139-44. PubMed ID: 27076751
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dual aromatase-steroid sulfatase inhibitors (DASI's) for the treatment of breast cancer: a structure guided ligand based designing approach.
    Singh Y; Jaswal S; Singh S; Verma SK; Thareja S
    J Biomol Struct Dyn; 2023 Dec; 41(20):10604-10626. PubMed ID: 36510679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.